Who owns Immunovant (IMVT)? Superinvestor holders
3 superinvestors of the 157 tracked here hold Immunovant (IMVT) in their latest 13F filing, with $431.6M between them. Andrew Spokes gives it the most weight: 1.14% of the reported portfolio. In their latest reported quarter, Andrew Spokes added; Julian and Felix Baker reduced.
Key facts
- Superinvestors holding it
- 3 of 157
- Biggest holder
- Andrew Spokes, $218.6M
- Largest weight
- Andrew Spokes, 1.14%of their portfolio
- Combined value
- $431.6M
- Bought last quarter
- 1
- Sold last quarter
- 1
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Andrew SpokesFarallon Capital Management | 1.14% | $218.6M | 6.47M | ▲ Added 11% | +665.85K | Q3 2026 |
| 2 | Julian and Felix BakerBaker Bros. Advisors | 1.05% | $209.4M | 5.44M | ▼ Reduced 0.4% | −22.92K | Q2 2026 |
| 3 | David EinhornGreenlight Capital | 0.09% | $3.6M | 93.52K | No change | 0 | Q2 2026 |
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 1 | 6.47M | $218.6M | 1 | 0 |
| Q2 2026 | 157 | 3 | 11.33M | $436.7M | 1 | 1 |
| Q1 2026 | 157 | 3 | 7.1M | $176.3M | 2 | 1 |
| Q4 2025 | 157 | 2 | 5.47M | $139M | 0 | 0 |
| Q3 2025 | 157 | 2 | 5.47M | $88.2M | 0 | 0 |
| Q2 2025 | 157 | 2 | 5.47M | $87.5M | 0 | 1 |
| Q1 2025 | 156 | 3 | 6.58M | $112.5M | 1 | 1 |
| Q4 2024 | 156 | 3 | 3.13M | $77.5M | 1 | 2 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Andrew Spokes | 6.47M | 5.81M | 1.55M | 12K | 12K | 12K | 12K | 12K |
| Julian and Felix Baker | · | 5.44M | 5.46M | 5.46M | 5.46M | 5.46M | 5.46M | 1.71M |
| David Einhorn | · | 93.52K | 93.52K | — | — | — | — | — |
| Andreas Halvorsen | · | — | — | — | — | — | 1.11M | 1.41M |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own IMVT?
In their latest 13F filings: Andrew Spokes (1.14% of the portfolio, $218.6M), Julian and Felix Baker (1.05% of the portfolio, $209.4M), David Einhorn (0.09% of the portfolio, $3.6M).
Who bought IMVT last quarter?
Andrew Spokes (added 11%). “Last quarter” is each investor's latest reported quarter.
Who sold IMVT last quarter?
Reduced: Julian and Felix Baker (0.4% fewer shares).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns Immunovant (IMVT)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/IMVT/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to IMVT by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.